Regulation of Cell Cycle and Cancer Development (G2960)

Target Name: GTF2E1

NCBI ID: G2960

GTF2E1

Regulation of Cell Cycle and Cancer Development

GTF2E1 (Growth arrest and DNA damage-inducible gene 2 homolog E1) is a non-coding RNA molecule that has been identified as a potential drug target (or biomarker) in the field of cancer. GTF2E1 is a key regulator of the cell cycle, and its abnormal expression has been linked to various types of cancer, including breast, ovarian, and prostate cancer.

The cell cycle is the process by which cells grow, divide, and replicate their genetic material. The cell cycle is regulated by a complex network of proteins that help ensure that each cell has the necessary amount of genetic material and that the cell divides properly. GTF2E1 is one of the proteins that is involved in the regulation of the cell cycle.

GTF2E1 is a non-coding RNA molecule that is made up of four exons. The four exons are located on the 5' and 3' ends of the RNA molecule, and they are involved in the regulation of the cell cycle.

The first exon of GTF2E1 is located at the 5' end of the RNA molecule, and it is responsible for introducing the GTF2E1 protein to the cell. The second exon is located at the 3' end of the RNA molecule, and it is responsible for the termination of the GTF2E1 protein.

The third and fourth exons of GTF2E1 are located on the 3' end of the RNA molecule, and they are involved in the regulation of the cell cycle. The third exon is responsible for the inhibition of the G1 checkpoint, which is a protein that helps ensure that the cell has enough genetic material before it divides. The fourth exon is responsible for the inhibition of the G2 checkpoint, which is a protein that helps ensure that the cell has enough genetic material before it divides.

GTF2E1 is a critical regulator of the cell cycle, and its aberrant expression has been linked to various types of cancer. For example, studies have shown that GTF2E1 is overexpressed in various types of cancer, including breast, ovarian, and prostate cancer. This overexpression of GTF2E1 has been shown to disrupt the regulation of the cell cycle, leading to the development of cancer.

In addition to its role in the regulation of the cell cycle, GTF2E1 has also been shown to play a role in the development and progression of cancer. For example, studies have shown that GTF2E1 is involved in the regulation of cell adhesion, a process that helps cells stick together and form tissues. This regulation is important for the development and progression of cancer, as cancer cells often have an abnormal ability to stick together and form tissues.

GTF2E1 is also involved in the regulation of cell signaling, which is the process by which cells communicate with each other and with their environment. This regulation is important for the development and progression of cancer, as cancer cells often have an abnormal ability to communicate with other cancer cells and with their environment.

In conclusion, GTF2E1 is a non-coding RNA molecule that is involved in the regulation of the cell cycle and the development and progression of cancer. Its abnormal expression has been linked to various types of cancer, including breast, ovarian, and prostate cancer. GTF2E1 is a potential drug target (or biomarker) that could be targeted with small molecules or other therapeutic agents to treat cancer. Further research is needed to fully understand the role of GTF2E1 in cancer development and to develop effective treatments.

Protein Name: General Transcription Factor IIE Subunit 1

Functions: Recruits TFIIH to the initiation complex and stimulates the RNA polymerase II C-terminal domain kinase and DNA-dependent ATPase activities of TFIIH. Both TFIIH and TFIIE are required for promoter clearance by RNA polymerase

The "GTF2E1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GTF2E1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets